Nuvectis Pharma (NVCT) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for June 12, 2025, to be held virtually, with voting on director election and auditor ratification.

• Proxy materials and annual report are available online, with paper copies upon request.

• Shareholders of record as of April 14, 2025, are eligible to vote; 23,606,443 shares outstanding.

• Board encourages all shareholders to vote, either in advance or during the meeting.

Voting matters and shareholder proposals

• Election of one Class III director, James Oliviero, for a three-year term expiring at the 2028 annual meeting.

• Ratification of Kesselman & Kesselman as independent registered public accounting firm for 2025.

• Shareholders may submit proposals for the 2026 annual meeting by December 29, 2025.

Board of directors and corporate governance

• Board consists of four directors, divided into three classes, with staggered three-year terms.

• Three directors are independent under Nasdaq rules; CEO also serves as Chairman.

• Board held six meetings in 2024; all directors attended at least 75% of meetings.

• No standing nominating committee; independent directors recommend nominees.

• Written code of business conduct and insider trading policy in place.